Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 23, 2011

Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples

  • Maartje I. Kester EMAIL logo , Wiesje M. van der Flier , Allerdien Visser , Marinus A. Blankenstein , Philip Scheltens and Cees B. Oudejans

Abstract

Background: A recent study reported that an 18-analyte multiplexed plasma panel of signaling proteins differentiated Alzheimer's disease (AD) from controls. This study measured mRNA expression for nine of these promising bio-markers in 23 AD patients and 23 age- and sex-matched controls.

Methods: Total RNA was isolated from PaxGene RNA tubes. Relative mRNA expression levels of CCL5 [RANTES], CSF1, ICAM1, IGFBP6, IL1A, IL3, IL8, PDGFB and TNF were determined by Q-RT-PCR, with GAPDH as housekeeping gene.

Results: A panel of five markers (CCL5, CSF1, ICAM1, IL8, TNF) with detectable expression levels in all individuals differed between AD patients and controls (p interaction <0.10). Especially, the relative expression level of CCL5 was lower in AD patients than in controls (p<0.005). Across groups, levels of both CCL5 and TNF were correlated to CSF levels of τ (r=0.39, r=0.32), pτ-181 (r=0.38, r=0.33), and MMSE (r=–0.31, r=–0.33, all p<0.05).

Conclusions: The measured panel, and especially CCL5, could aid in the differentiation of AD from controls.


Corresponding author: Maartje I. Kester, Alzheimer Center, Department of Neurology, VU University Medical Center Amsterdam, PO Box 7057, 1007 MB Amsterdam, The Netherlands Phone: +31 20 4440183, Fax: +31 20 4440715

Received: 2011-5-3
Accepted: 2011-9-5
Published Online: 2011-09-23
Published in Print: 2012-01-01

©2011 by Walter de Gruyter Berlin Boston

Downloaded on 24.5.2024 from https://www.degruyter.com/document/doi/10.1515/cclm.2011.731/html
Scroll to top button